business-header.jpg

Anti-Viral Drug

Currently, several antiviral, such as synthetic drugs and interferon, are available on the market which still have many limitations in their clinical applications. The continued use of chemical drugs can lead to increased resistance and although interferon shows a broad spectrum of antiviral activity in dealing with the range of viruses, its activity is not as effective as people had expected. Developed countries like the USA have started realizing the potential of composite materials possessing promising results.

A number of possibilities have been discussed in various research papers, which are a good start, but the methods to obtain such substances are yet in the early elementary stage. So far, methods for its purification have not been standardized. We have conducted extensive research for decades and have developed techniques to obtain the proprietary source material (VSF: Virus Suppressing Factor). The company received a USA Patent in April 2010 and is ready to submit a patent regarding an appropriated human VSF worldwide.

Novel Antiviral Therapeutics

According to reports, the expected market size of antiviral agents is about 30 billion USD. Since a significant portion of all incurable diseases are viral diseases, the antiviral market has a tremendous growth potential.

Existing antiviral products are still in their elementary stage in the market. Chemical drugs, due to their increasing resistance and side effects, have limited usages. Despite its low efficacy, the worldwide sales for interferon are about 11 billion USD.

Considering the future development, a new antiviral drug such as VSF, will create a new break though and significantly a huge market leading to the expansion of the total antiviral therapeutics market. Therefore, the current market size of 30 billion USD for antiviral therapeutics is expected to expand considerably.

What is VSF?

According to reports, the expected market size of antiviral agents is about 30 billion USD. Since a significant portion of all incurable diseases are viral diseases, the antiviral market has a tremendous growth potential.

VSF is produced in the body, similar to that of interferon; however it shows much greater antiviral activity over a wider range of viruses in animal experiments than interferon. Therefore, if developed as an antiviral therapeutic, VSF can overcome many of the limitations of the existing synthetic antiviral as well as interferon.
business-sub

Business Prospects

  • Features and Advantages of VSF
  • Strong in vitro and in vivo antiviral activity.
  • No resistance and little or no side effects due to its origin in the body.
  • Utilizes innate immunity acts on the cells which is effective against a wide range of viruses.
  • Due to our excellent proprietary technology to develop VSF for over 20 years, no other competitor can
    easily attempt to discover and develop biologically active VSF with composite nature.

Once appropriation of VSF is completed and the 3rd stage of Korean clinical trials begins, our company’s value is expected to exceed the company value of the leading Korean pharmaceutical companies. If clinical trials succeed, ImmuneMed Inc. will have the foundation to become a leading global pharmaceutical company in the near future.

Plans and Prospects

  • Projected research required for the development of the new antiviral drug before clinical trials: to be
    completed by 2012.
  • Genetic Identification: Step 1 identification is complete, human recombinant protein and its appropriation
    is under development.
  • Domestic Clinical Trials: It will start in cooperation with Seoul National University, Korea University and
    Hallym University Medical Schools in 2013 and will be completed in 2015.
  • U.S. Clinical Trials: After analyzing results from the domestic clinical trials, in cooperation with some
    multinational pharmaceutical companies, they will be conducted from 2014 to 2017.